Blood Cancers

FDA approves BESREMi for adults with essential thrombocythemia, offering a new treatment option for people living with this rare blood cancer.

FDA approves Mimrylo (rusfertide) for adults with polycythemia vera, offering a new treatment approach that may reduce the need for frequent blood draws.

Nona Baker discusses the misdiagnoses that came first, why families need support and what has changed since.

Before starting cell therapy, patients need more than hope — they need a plan. Dr. Muhammad Tariq breaks down what to expect at each step.

FDA approves Tregzi, a new cell therapy that helps reduce chronic graft-versus-host disease after donor stem cell transplant in adults with blood cancers.

Six years after remission, a survivor reflects on scan anxiety, recurrence fears, and the uncertainty of living with chronic cancer.

Updated COMMANDS trial data show Reblozyl improved survival and long-term transfusion independence vs. Epogen in lower-risk MDS patients.

FDA approves Decnupaz for adults with BPDCN, with 69.7% of treatment-naïve patients achieving remission in the CADENZA trial.

Dr. Gwen Nichols explains how Orca‑T may reduce graft-versus-host disease and impact treatment decisions for certain patients with blood cancers.

2025 brought key advances in blood cancer treatment, research, and patient insights across multiple myeloma, lymphoma, leukemia and MDS.

All I can say is thank you Healthwell Foundation for giving our brother life, and for giving our whole family unit life. Because of you, we can keep on keeping on.

I attended this year’s Light the Night walk in remembrance of my sister, reflecting on her 11-year battle and enduring identity as a cancer survivor.

CURE spoke with Dr. Dickran Kazandjian about why MRD matters for patients with multiple myeloma.

Lore Gruenbaum, chief scientific officer of Blood Cancer United, sat down for an interview with CURE to discuss the themes shaping blood cancer care today.

Xervyteg improved responses and was safe in steroid- and Jakafi-resistant acute graft-versus-host disease affecting the GI tract in a phase 3 trial.

Transitioning treatment with Niktimvo to a dose of 0.6 mg/kg every four weeks appeared feasible for chronic graft-versus-host disease.

Dr. Matthew Matasar discusses why stem cell transplant is still a standard, life-saving option in blood cancers and how CAR-T cell therapy is changing treatment decisions.

The FDA granted fast track status to UB-VV111 for patients with relapsed or refractory large B-cell lymphoma or chronic lymphocytic leukemia.

Dr. Christina Cho explains that a strong transplant program provides advanced treatments along with a supportive team for patients with blood cancers.

The Leukemia & Lymphoma Society (LLS) is now Blood Cancer United.

Your diagnosis of an early-stage blood cancer, such as a MPN or MDS, means that something has changed in the way your bone marrow produces blood cells.

Dr. Olalekan O. Oluwole, discusses treating patients from underserved communities with CAR T-cell therapy, as well as highlighted the therapy's evolution.

Doptelet and new oral sprinkle granules is approved for children one year and older with chronic immune thrombocytopenia, showing 28% durable platelet response in study.

Daniel Jernazian, a two-time cancer survivor, shares how sports, advocacy and meeting his idol shaped his journey through illness and recovery.